Incyte posts results of Phase 3 povorcitinib trial in hidradenitis suppurativa
The study enrolled 619 participants and completed its primary phase on January 7, 2025. Results were first posted on ClinicalTrials.gov on November 5, 2026.
Primary source
ClinicalTrials.gov results record, November 5, 2026
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
Read the source: A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation